Evaluation of the survival-inferred fragility index to assess the robustness of the estimated treatment effect on survival endpoints
The SIFI should not be used as a measure of robustness of survival trials, as it relates to a very specific group of individuals. At least, a random selection of patients should be used in its calculation.
Authors
- Roland Couturier
- Jérôme Lambert (ORCID: https://orcid.org/0000-0001-7086-9295)
- Sylvie Chevret (ORCID: https://orcid.org/0000-0001-6449-4730)
Institutions
- Inserm (FR)
- Institut Universitaire de France (FR)
- Université Paris Cité (FR)
- Eau de Paris (France) (FR)
- Centre de Recherche Épidémiologie et Statistique (FR)
Publication Details
- Journal
- Contemporary Clinical Trials
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.cct.2025.107906
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00